NCT00930475View on ClinicalTrials.gov

Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

RAD001 (Everolimus) in combination with carboplatin

phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress

DRUG

RAD001 (Everolimus) in combination with carboplatin

phase 2: 10mg RAD001 in combination with carboplatin

Trial Locations (1)

10177

RECRUITING

Charité, university medicine, Berlin, CCM, Berlin

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

KKS Netzwerk

NETWORK

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER